NOW FDA APPROVED

See our press release

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-250033 03/25

Contact Us Careers
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers
×
  • Home
  • About
    • Mission
    • Leaders
  • Products
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
  • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
  • Careers

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Apr 29, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Mar 20, 2025

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Mar 4, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 3, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 31, 2024

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 2, 2024

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Nov 14, 2024
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...31

    © 2025 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy Terms of Use